REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

General Discussion
5

Tirzepatide vs Semaglutide for weight management

Marley Chen 36·4 days ago
I have been tracking my progress with spreadsheets and regular blood work. The data tells an interesting story. Sharing my complete protocol details for transparency.

Comments (4)

Morgan Santos 653·about 2 months ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Morgan Ali 753·about 1 month ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Morgan Novak 853·21 days ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2
Morgan Patel 53·4 days ago

This is exactly the kind of detailed report the community needs. Too much broscience out there. Appreciate the data-driven approach.

2

Sign in to comment.